Immunic, Inc. (IMUX)
NASDAQ: IMUX · Real-Time Price · USD
0.6599
-0.0202 (-2.97%)
At close: May 30, 2025, 4:00 PM
0.6700
+0.0101 (1.53%)
After-hours: May 30, 2025, 7:59 PM EDT
Immunic Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
91
Market Cap
63.23M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
IMUX News
- 2 days ago - Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering - PRNewsWire
- 3 days ago - Immunic, Inc. Announces Proposed Public Offering - PRNewsWire
- 4 weeks ago - Immunic to Participate in Scientific and Industry Conferences in May - PRNewsWire
- 4 weeks ago - Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial - PRNewsWire
- 4 weeks ago - Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher - Seeking Alpha
- 7 weeks ago - Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments - PRNewsWire
- 7 weeks ago - Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments - PRNewsWire
- 2 months ago - Immunic, Inc. to Participate in Scientific and Industry Conferences in April - PRNewsWire